A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4)
Stopped The termination of FIN-CDI-301 (PRISM4) is based on the voluntary, business-related decision of the sponsor.
Conditions
- Recurrent C. Difficile Infection
Interventions
- BIOLOGICAL: CP101
- OTHER: Placebo
Sponsor
Finch Research and Development LLC.